Literature DB >> 23319137

Targeted therapies: Priming apoptosis.

M Teresa Villanueva.   

Abstract

Year:  2013        PMID： 23319137     DOI： 10.1038/nrclinonc.2012.241

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.

Authors:  Mohamed Rahmani; Mandy Mayo Aust; Elisa Attkisson; David C Williams; Andrea Ferreira-Gonzalez; Steven Grant
Journal:  Cancer Res       Date:  2012-12-12       Impact factor: 12.701

2.  Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.

Authors:  Ryan B Corcoran; Katherine A Cheng; Aaron N Hata; Anthony C Faber; Hiromichi Ebi; Erin M Coffee; Patricia Greninger; Ronald D Brown; Jason T Godfrey; Travis J Cohoon; Youngchul Song; Eugene Lifshits; Kenneth E Hung; Toshi Shioda; Dora Dias-Santagata; Anurag Singh; Jeffrey Settleman; Cyril H Benes; Mari Mino-Kenudson; Kwok-Kin Wong; Jeffrey A Engelman
Journal:  Cancer Cell       Date:  2012-12-13       Impact factor: 31.743
  2 in total
  2 in total

Review 1.  Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.

Authors:  Pankit Vachhani; Prithviraj Bose; Mohamed Rahmani; Steven Grant
Journal:  Physiol Genomics       Date:  2014-05-13       Impact factor: 3.107

2.  ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins.

Authors:  Clara Alcon; Jorge Gómez Tejeda Zañudo; Reka Albert; Nikhil Wagle; Maurizio Scaltriti; Anthony Letai; Josep Samitier; Joan Montero
Journal:  Cells       Date:  2021-07-02       Impact factor: 6.600
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.